Signals, Powered By EquityPandit
The US health regulator has provided its approval to the drug major Lupin to market its memantine hydrochloride extended release capsules that are used in treating Alzheimer’s disease.
Lupin has said in a regulatory filing that the company has received final approval for the product in strengths of 7 mg, 14 mg, 21 mg, and 28 mg, from the US Food and Drug Administration (USFDA).
The product of the company is a generic version of Allergan’s Namendra XR capsules that are indicated for treatment of moderate to severe dementia of the Alzheimer’s type.
